# GMMG HD7 (NCT03617731)

> Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03617731
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Heidelberg Medical Center
- Conditions: Multiple Myeloma
- Interventions: Lenalidomide; Bortezomib; Dexamethasone; Isatuximab
- Enrollment: 662
- Primary outcome: MRD negativity after induction Treatment (comparison of arms IA and IB)
- Primary outcome: Progression Free Survival (PFS) after second randomization (arms IIA and IIB)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gmmg-hd7-nct03617731